[BMY] Bristol-Myers Squibb Company


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 128.21 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 59.6 Change: 0.82 (1.4%)
Ext. hours: Change: 0 (0%)

chart BMY

Refresh chart

Strongest Trends Summary For BMY

BMY is in the long-term up 235% in 23 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products

Fundamental Ratios
Shares Outstanding1.67 B EPS2.51 EPS Growth - 4 Quarters-704.03% EPS Growth - Q/Q-233.04%
EPS Growth - Y/Y-255.12% Sales Growth - 4 Quarters 6.17% Sales Growth - Q/Q3.02% P/E21.7
P/E To EPS Growth0.28 P/S7.83 P/BV8.48 Price/Cash Per Share23.41
Price/Free Cash Flow48.9 ROA5.6% ROE11.84% ROI7.56%
Current Ratio1.76 Quick Ratio1.58 Long Term Debt/Equity1.18 Debt Ratio0.49
Gross Margin76.6% Operating Margin14.94% Net Profit Margin10.93% Dividend Payout Ratio-136.15%
Dividend Yield-1.9%
Fundamental Data
Cash From Financing Activities-1.57 B Cash From Investing Activities-526 M Cash From Operating Activities697 M Gross Profit3.18 B
Net Profit-130 M Operating Profit45 M Total Assets31.95 B Total Current Assets13.06 B
Total Current Liabilities7.44 B Total Debt7.37 B Total Liabilities16.83 B Total Revenue4.16 B
Technical Data
High 52 week62.66 Low 52 week42.77 Last close47.32 Last change0.06%
RSI79.2 Average true range1.11 Beta0.67 Volume5.04 M
Simple moving average 20 days5.46% Simple moving average 50 days3.65% Simple moving average 200 days-1.71%
Performance Data
Performance Week2.89% Performance Month6.27% Performance Quart1.55% Performance Half-4.95%
Performance Year-20.85% Performance Year-to-date-8.14% Volatility daily1.49% Volatility weekly3.34%
Volatility monthly6.85% Volatility yearly23.72% Relative Volume180.93% Average Volume13.49 M
New High New Low


2020-05-23 08:00:08 | Teladoc, Neurocrine Bio Lead Five Healthy Stocks To Monitor Closely

2020-05-22 11:10:33 | FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

2020-05-22 06:59:00 | European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel Ide-cel, bb2121 and CC-486

2020-05-21 17:40:56 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT

2020-05-21 15:48:12 | Fmr. CDC Official: 'we’re not cutting any corners' on COVID-19 vaccine development

2020-05-21 14:24:29 | Clovis Oncology Needs a Savior

2020-05-20 07:03:00 | Could This Cancer Drug Developer’s Stock Make You Filthy Rich?

2020-05-20 06:59:00 | Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases

2020-05-19 21:13:16 | 10 Stocks Hedge Funds Are Crazy About Right Now

2020-05-19 18:53:20 | 8 Biotechs Tapping Secondary Markets for $3 Billion

2020-05-19 15:18:55 | Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'

2020-05-19 12:45:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT

2020-05-19 07:19:24 | Bluebird Prices New Shares At $55, Seeks To Raise $500 Million

2020-05-18 14:54:56 | We anticipate a U-Shaped to Swoosh-Shaped recovery: Strategist

2020-05-18 14:47:12 | Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert

2020-05-18 11:45:03 | Why Bristol-Myers Squibb BMY is a Great Dividend Stock Right Now

2020-05-18 11:40:03 | BMY or MRK: Which Is the Better Value Stock Right Now?

2020-05-18 10:58:02 | Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC

2020-05-17 14:03:00 | Better Buy: Pfizer vs. Bristol Myers Squibb

2020-05-16 10:43:00 | Bristol Myers Squibb's Cancer Combo Gets a Green Light from the FDA

2020-05-15 16:20:18 | Jim Simons' Top Buys of the 1st Quarter

2020-05-15 15:56:00 | U.S. Food and Drug Administration Approves Opdivo® nivolumab + Yervoy® ipilimumab as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1?1%

2020-05-15 15:13:45 | U.S. FDA approves Bristol Myers' combo therapy for lung cancer

2020-05-15 13:24:03 | The Top 6 Buys of John Rogers' Ariel Investments

2020-05-15 12:18:13 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY.RT

2020-05-15 10:45:02 | Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY

2020-05-15 08:53:00 | U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® pomalidomide for AIDS-Related and HIV-Negative Kaposi Sarcoma

2020-05-15 08:30:00 | 3 Stocks to Buy Ahead of the Next Market Crash

2020-05-14 14:01:06 | The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

2020-05-14 11:30:00 | BMY.RT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bristol-Myers Squibb Company and Encourages Investors to Contact the Firm

2020-05-14 11:13:36 | Bristol-myers Squibb In Buy Range

2020-05-14 09:23:01 | Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA

2020-05-13 17:12:11 | Bluebird Bio Stock Dives After FDA Rejects Bristol-Partnered Cancer Drug

2020-05-13 17:00:00 | Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo nivolumab Plus Yervoy ipilimumab vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Patients with PD-L1 ?1%

2020-05-13 17:00:00 | Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

2020-05-13 17:00:00 | Opdivo nivolumab Plus Yervoy ipilimumab with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic Non-Small Cell Lung Cancer in CheckMate -9LA Study

2020-05-13 13:15:00 | Bristol-Myers to Resubmit Myeloma-Drug Bid to FDA - Here's the Trade

2020-05-13 11:57:29 | A Look at the Deep Value Stocks of Kahn Brothers

2020-05-13 10:41:00 | Bristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma Treatment

2020-05-13 09:49:00 | Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline

2020-05-13 09:34:01 | Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

2020-05-13 08:06:51 | U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma

2020-05-13 07:45:00 | Bluebird, Bristol-Myers Squibb have resubmit FDA bid for CAR-T therapy

2020-05-13 07:15:20 | U.S. FDA decides to not review Bristol Myers, bluebird therapy for multiple myeloma

2020-05-13 06:59:00 | Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel ide-cel, bb2121 for the Treatment of Patients with Multiple Myeloma

2020-05-13 06:10:00 | Is Bristol Myers Squibb Losing Its Edge As A Growth Stock?

2020-05-12 18:39:02 | IBD 50 Stocks To Watch: Pharmaceutical Leader Bristol Myers Squibb In Buy Range After Breakout

2020-05-12 17:07:43 | Hedge Fund Tells Alexion Management to Sell Company

2020-05-12 14:29:35 | Dow Jones Fights To Hold 10% Gain In Q2; Three Large Cap Stocks Clear Buy Points

2020-05-12 12:45:04 | Bristol-Myers BMY is an Incredible Growth Stock: 3 Reasons Why